Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.
Comron Hassanzadeh, Deborah Kuban, Sarah Pasyar, Roland Bassett, Patricia Troncoso, Maheen Ansari, Pamela Schlembach, Sean McGuire, Quynh Nguyen, Steven Frank and 8 more
Abstract readClinical Trial, Phase IIIRandomized Controlled TrialComparative Study
In one paragraphTrial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Comron HassanzadehDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-8107-2799 Deborah KubanDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sarah PasyarDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Roland BassettDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4534-2042 Patricia TroncosoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Maheen AnsariDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Pamela SchlembachDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sean McGuireDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Quynh NguyenDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7062-575X Steven FrankDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6517-7884 Henry MokDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Osama MohamadDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-2972-657X Ryan ParkDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-4725-2937 Chad TangDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5915-1327 Weiliang DuDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6644-9802 Rajat KudchadkerDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Seungtaek ChoiDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Karen HoffmanDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
6 · The paper itselfAbstract
The MD Anderson dose-escalated, hypofractionated prostate radiation study was a phase III randomized trial comparing conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75.6 Gy in 1.8-Gy fractions) with dose-escalated, hypofractionated intensity-modulated radiation (HIMRT, 72 Gy in 2.4-Gy fractions) in patients with localized prostate cancer, predominantly low-risk and intermediate-risk disease. The initial publication highlighted statistically fewer treatment failures in the HIMRT arm. We present long-term updated 13-year outcomes to determine whether cancer control benefit was maintained and to evaluate distant metastases post hoc. With a median follow-up of 13.2 years (IQR, 8.8-15.9 years), treatment failure occurred less frequently in men undergoing HIMRT (n = 13) compared with those undergoing CIMRT (n = 22), although the difference no longer meets statistical significance (
Indexed as
Prostatic NeoplasmsRadiation Dose HypofractionationRadiotherapy, Intensity-ModulatedAgedDose Fractionation, RadiationHumansMaleMiddle AgedProspective Studies
Identifiers
PMID40367400
PMCPMC12170155
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390